Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
16 angezeigte Treffer · Seite 1, keine Gesamtzahl für „lorlatinib“
Suchtreffer
Begriffe & Kennungen
Lorlatinib
Eintrag öffnenLorviqua · 4.3 · Hypersensitivity to lorlatinib or to any of the excipients listed in section 6.1.
Eintrag öffnenLorviqua · 4.5 · Effect of lorlatinib on other medicinal products
Eintrag öffnenLorviqua · 4.5 · Effect of medicinal products on lorlatinib
Eintrag öffnenLorviqua · 4.5 · In vitro data indicate that lorlatinib is primarily metabolised by CYP3A4 and uridine diphosphate-glucuronosyl
Eintrag öffnenLorviqua · 4.5 · In vitro studies indicated that lorlatinib is a time-dependent inhibitor as well as an inducer of CYP3A4/5. Lo
Eintrag öffnenLorviqua · 4.5 · In vitro studies indicated that lorlatinib may have the potential to inhibit BCRP (gastrointestinal tract), OA
Eintrag öffnenLorviqua · 4.5 · In vitro, lorlatinib has a low potential to cause drug-drug interactions by induction of CYP1A2.
Eintrag öffnenLorviqua · 4.5 · Lorlatinib 100 mg once daily for 15 days decreased AUCinf and Cmax of a single oral 100 mg dose of bupropion (
Eintrag öffnenLorviqua · 4.5 · Lorlatinib 100 mg once daily for 15 days decreased AUCinf and Cmax of a single oral 500 mg dose of acetaminoph
Eintrag öffnenLorviqua · 4.5 · Lorlatinib 100 mg once daily for 15 days decreased AUCinf and Cmax of a single oral 500 mg dose of tolbutamide
Eintrag öffnenLorviqua · 4.5 · Lorlatinib 100 mg once daily for 15 days decreased AUCinf and Cmax of a single oral dose of 60 mg fexofenadine
Eintrag öffnenLorviqua · 4.8 · Dose reductions due to adverse reactions occurred in 20.1% of patients receiving lorlatinib. The most common a
Eintrag öffnenLorviqua · 4.8 · Serious adverse reactions were reported in 9.1% of patients receiving lorlatinib. The most frequent serious ad
Eintrag öffnenLorviqua · 4.8 · Table 2 presents adverse reactions occurring in 547 adult patients treated with lorlatinib 100 mg once daily w
Eintrag öffnenlorlatinib
Eintrag öffnen